ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has officially announced an upcoming milestone as it prepares to unveil its financial and operational outcomes for the third quarter of 2024, slated for release prior to the market’s opening on November 7, 2024, a key date for investors and analysts following the company.
Aurinia’s management team will host a conference call and engaging webcast at 8:30 am ET that day to thoroughly review these important results and offer a comprehensive update on the company’s current business initiatives and strategic direction.
Webcast & Conference Call Details
The link to the audio webcast is available here. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963, ensuring to enter the Conference ID: 6251719 or specify the company name for seamless access. A replay of the webcast will be conveniently available on Aurinia’s official website for those unable to attend live.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company dedicated to delivering innovative therapies for individuals affected by autoimmune diseases, particularly those facing significant unmet medical needs. In a groundbreaking move in January 2021, the Company launched LUPKYNIS® (voclosporin), the first FDA-approved oral treatment specifically designed for adult patients battling active lupus nephritis. Additionally, Aurinia is actively advancing AUR200, a differentiated therapeutic option that poses potential as a best-in-class treatment for autoimmune maladies, strategically targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
Contacts
Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
[email protected]
General Investor Inquiries:
[email protected]
**Interview with Jane Smith, Financial Analyst at BioPharma Insights**
**Interviewer:** Good afternoon, Jane! With Aurinia Pharmaceuticals set to report its Q3 earnings on November 7, 2024, what should investors be particularly focused on in this upcoming announcement?
**Jane Smith:** Good afternoon! Investors should pay close attention to the company’s revenue growth and any updates on product performance, especially related to their flagship drug, Lupkynis. It will be interesting to see how the drug’s sales have trended over the past quarter and how Aurinia plans to position itself in the competitive market.
**Interviewer:** Aurinia will also hold a conference call and webcast that morning. How important are these sessions for stakeholders?
**Jane Smith:** Extremely important! The conference call provides a platform for the management team to discuss the quarter’s results in detail and to share insights into future strategies. It’s an opportunity for investors to get a more nuanced understanding of the company’s operational goals and challenges directly from leadership.
**Interviewer:** Are there specific questions or themes you think analysts will focus on during this call?
**Jane Smith:** Yes, I anticipate that analysts will probe about the impact of recent regulatory changes and how they may affect Aurinia’s operations. They may also inquire about partnership developments and any ongoing clinical trials, as those factors can significantly influence the company’s future growth trajectory.
**Interviewer:** With the financial results being released before the market opens, how do you expect the market to react?
**Jane Smith:** That will depend largely on whether the results meet, exceed, or fall short of market expectations. If the earnings support positive guidance and reveal strong sales performance, we can expect a favorable reaction. Conversely, any disappointment could lead to stock volatility, so it will be crucial to watch how the results align with investor sentiment.
**Interviewer:** Great insights, Jane! It will definitely be interesting to see how Aurinia navigates this critical reporting period. Thank you for your time!
**Jane Smith:** Thank you for having me! I’m looking forward to the announcement as well.
